Clinical use of checkpoint inhibition in kidney cancer.
نویسنده
چکیده
501. 3. Hammers HJ, Plimack ER, Infante JR, et al. Expanded cohort results from CheckMate 016: a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) [ASCO abstract 4516]. J Clin Oncol. 2015;33(15)(suppl). 4. McDermott DF, Sznol M, Sosman JA, et al. Immune correlates and long term follow up of a phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC). Paper presented at: European Society for Medical Oncology Congress; September 26-30, 2014; Madrid, Spain. Abstract 8090. 5. Choueiri TK, Plimack ER, Gupta S, et al. Phase lb dose-finding study of axitinib plus pembrolizumab in treatment-naive patients with advanced renal cell carcinoma. BJU Int. 2015;116(suppl 5):5.
منابع مشابه
Whole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15
Cancer immunotherapy (passive or active) involves treatments which promote the ability of the immune system to fight tumor cells. Several types of immunotherapeutic agents, such as monoclonal antibodies, immune checkpoint inhibitors, non-specific immunomodulatory agents, and cancer vaccines are currently under intensive investigation in preclinical and clinical trials. Cancer vaccines induce pe...
متن کاملDendritic Cell Immunotherapy, the Next Step in Cancer Treatment
Cancer immunotherapy has gained a lot of interest over the past few years due to the success of immune checkpoint inhibitors in treating cancer (1, 2). Immune checkpoint inhibitors, such as monoclonal antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), have been shown to increase survival of patients with advanced cancers (1, 2). These in...
متن کاملRe: miR-28-5p promotes chromosomal instability in VHL-associated cancers by inhibiting Mad2 translation.
Chromosomal instability enables tumor development, enabled in part by aberrant expression of the mitotic checkpoint protein Mad2. Here we identify a novel regulatory mechanism for Mad2 expression involving miR-28-5p-mediated inhibition of Mad2 translation, and we demonstrate that this mechanism is triggered by inactivation of the tumor suppressor VHL, the most common event in clear cell renal c...
متن کاملImmune Checkpoint Inhibition and the Prevalence of Autoimmune Disorders Among Patients With Lung and Renal Cancer
PURPOSE Immune checkpoint inhibition reactivates the immune response against cancer cells in multiple tissue types and has been shown to induce durable responses. However, for patients with autoimmune disorders, their conditions can worsen with this reactivation. We sought to identify, among patients with lung and renal cancer, how many harbor a comorbid autoimmune condition and may be at risk ...
متن کاملDendritic Cell Immunotherapy, the Next Step in Cancer Treatment
Cancer immunotherapy has gained a lot of interest over the past few years due to the success of immune checkpoint inhibitors in treating cancer (1, 2). Immune checkpoint inhibitors, such as monoclonal antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), have been shown to increase survival of patients with advanced cancers (1, 2). These in...
متن کاملThe science of checkpoint inhibition in kidney cancer.
Immunotherapy has offered the hope of a cancer cure for 100 years, according to Gordon J. Freeman, PhD. Although a cure remains elusive, “the door is now open,” Dr Freeman said. Programmed death 1 (PD-1) inhibitors have provided “a good foundation to build upon” for the treatment of kidney cancer and other cancers. Dr Freeman, who is a professor of medicine at Harvard Medical School in Boston, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Clinical advances in hematology & oncology : H&O
دوره 14 6 شماره
صفحات -
تاریخ انتشار 2016